THRV-1268 Maintained a Near-Normal Ejection Fraction and Outperformed Empagliflozin Monotherapy in a Validated Model of Heart Failure; Phase 1 Studies Demonstrated Favorable Safety Profile and QTcF Shortening SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Thryv Therapeutics Inc. ("Thryv"),...
Hence then, the article about thryv therapeutics announces jacc heart failure publication of converging human genetic preclinical and clinical evidence supporting phase 2a development of lead sgk1 inhibitor thrv 1268 in heart failure was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure )
Also on site :
- 1966 Bob Dylan Hit, Ranked Among ‘Greatest Songs of All Time,’ Was Recorded in One Take on Valentine’s Day
- ‘The Late Show With Stephen Colbert’ Wins at 2026 Primetime Emmys: ‘Widow’s Bay,’ Bad Bunny’s Super Bowl Halftime & More Big Winners
- New Medicare and Medicaid GLP-1 Programs Spotlight Lifestyle Support as Menu-Order AI Launches Daily GLP-1 Habit Tracker, Helping Users Stay on Track